# Simron Singh

Source: https://nuclide.cc/people/simron-singh/  
Nuclide record `simron-singh` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours.

## Summary

Simron Singh was principal investigator of NETTER-2, which showed first-line 177Lu-DOTATATE plus octreotide dramatically improves progression-free survival over high-dose octreotide in grade 2-3 gastroenteropancreatic neuroendocrine tumours, extending radioligand therapy to newly diagnosed patients. He has led Canadian and international NET guidelines and studies of NET epidemiology and patient-reported outcomes.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: neuroendocrine; radioligand; canada
- Role: Medical Oncologist and Co-Director, Susan Leslie Clinic for Neuroendocrine Tumours, Sunnybrook Odette Cancer Centre
- Specialisms: Neuroendocrine tumours; Radioligand therapy; Health services research; Guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/)
- technologies: [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [Somatostatin receptor 2](https://nuclide.cc/targets/sstr2/)
- drugs: [Lutetium-177 dotatate](https://nuclide.cc/drugs/lutathera/)
- key papers: [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/)

---
JSON: https://nuclide.cc/api/v1/entities/simron-singh.json